Mirati Therapeutics, Inc.
MRTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $3 | $8 | $10 | $5 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $7 | $9 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -82.7% | 438.1% | 301.7% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 95.2% | -605.5% | -2,134.3% | -5,383.2% |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | -6,084.4% | -792.6% | -2,752.1% | -6,652.3% |
| Net Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -5,957.4% | -807% | -2,671.6% | -6,394.5% |
| EPS Diluted | -13.18 | -11.21 | -7.96 | -5.69 |
| % Growth | -17.6% | -40.8% | -39.9% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | -$0 | -$0 | -$0 |